539561 SUPHA

Supha Pharmachem Share Price

 

 

Start SIP in SUPHA

Start SIP

Performance

  • Low
  • ₹1
  • High
  • ₹1
  • 52 Week Low
  • ₹1
  • 52 Week High
  • ₹3
  • Open Price₹1
  • Previous Close₹1
  • Volume1,417,510
  • 50 DMA₹0.93
  • 100 DMA₹1.09
  • 200 DMA₹1.71

Investment Returns

  • Over 1 Month + 12.35%
  • Over 3 Month -37.67%
  • Over 6 Month -24.79%
  • Over 1 Year -66.79%

Smart Investing Starts Here Start SIP with Supha Pharmachem for Steady Growth!

Invest Now

Supha Pharmachem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -37
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 80
  • P/B Ratio
  • 0.9
  • Average True Range
  • 0.04
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0
  • RSI
  • 58.4
  • MFI
  • 63.6

Supha Pharmachem Financials

Supha Pharmachem Technicals

EMA & SMA

Current Price
₹0.91
0 (0%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹0.88
  • 50 Day
  • ₹0.93
  • 100 Day
  • ₹1.09
  • 200 Day
  • ₹1.71

Resistance and Support

0.91 Pivot Speed
  • R3 0.94
  • R2 0.93
  • R1 0.92
  • S1 0.90
  • S2 0.89
  • S3 0.88

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Supha Pharmachem has an operating revenue of Rs. 629.68 Cr. on a trailing 12-month basis. An annual revenue de-growth of -94% needs improvement, Pre-tax margin of 1% needs improvement, ROE of 4% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 3 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 10 indicates it belongs to a strong industry group of Leisure-Products and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Supha Pharmachem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-14 Quarterly Results
2025-11-14 Quarterly Results
2025-09-22 Rights Issue & Others To consider 1. Increase in Authorised Capital. to consider 1. Letter of Offer for the proposed Rights Issue of 49,19,04,000 Equity Shares of Re. 1/- each, aggregating to 4919.04 lakhs for shareholders. 2. Other business matters.
2025-08-04 Quarterly Results
2025-05-30 Audited Results
Date Purpose Remarks
2024-02-23 Split Rs.0.00 split from Rs. 5/- to Re. 1/-..
2023-09-01 Split Rs.0.00 split from Rs. 10/- to Rs. 5/-.
Date Purpose Remarks
2024-07-06 Bonus Rs.0.00 issue of equity shares in the ratio of 3:1 of Rs. 10/-.
2023-07-29 Bonus Rs.0.00 issue of equity shares in the ratio of 9:5 of Rs. 10/-.

Supha Pharmachem F&O

Supha Pharmachem Shareholding Pattern

1.13%
1.7%
81.29%
15.88%

Supha Pharmachem FAQs

Supha Pharmachem share price is ₹0 As on 12 February, 2026 | 06:31

The Market Cap of Supha Pharmachem is ₹80.3 Cr As on 12 February, 2026 | 06:31

The P/E ratio of Supha Pharmachem is -37 As on 12 February, 2026 | 06:31

The PB ratio of Supha Pharmachem is 0.9 As on 12 February, 2026 | 06:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23